{"id":22,"date":"2025-04-05T01:38:50","date_gmt":"2025-04-05T01:38:50","guid":{"rendered":"https:\/\/www.marketresearch.co.jp\/reports\/?p=22"},"modified":"2025-04-05T01:38:50","modified_gmt":"2025-04-05T01:38:50","slug":"global-next-generation-iv-infusion-pumps-market-size-share-and-growth-forecast-from-2025-2032","status":"publish","type":"post","link":"https:\/\/www.marketresearch.co.jp\/reports\/global-next-generation-iv-infusion-pumps-market-size-share-and-growth-forecast-from-2025-2032\/","title":{"rendered":"Global Next Generation IV Infusion Pumps Market Size, Share, and Growth Forecast from 2025 – 2032"},"content":{"rendered":"

Global Next-Generation IV Infusion Pumps Market Overview (2025\u20132032)<\/h3>\n

The global market for next-generation IV infusion pumps is projected to experience robust growth over the forecast period, expanding from USD 3.2 billion in 2025<\/strong> to approximately USD 5.58 billion by 2032<\/strong>, reflecting a compound annual growth rate (CAGR) of 7.3%<\/strong>. This growth is primarily driven by the increasing adoption of smart infusion technologies across hospital, homecare, and ambulatory settings, combined with the rising burden of chronic illnesses and the demand for error-free drug delivery systems.<\/p>\n

\"\"<\/p>\n

Infusion pumps are critical to modern medical care, enabling precise, controlled delivery of fluids, medications, and nutrients into a patient’s bloodstream. With growing technological advancements, the next generation of infusion pumps includes smart systems equipped with dose error reduction software (DERS), wireless connectivity, automated alerts, and integration with electronic health records (EHRs). These features reduce the risks of medication errors and improve overall patient outcomes.<\/p>\n

Historically, from 2019 to 2024, the market grew at a CAGR of 5.8%<\/strong>, fueled by rising hospital admissions and increasing reliance on advanced intravenous therapies. In 2024 alone, large volumetric infusion systems represented approximately USD 982.6 million<\/strong> in value, with the overall market accounting for 6.6% of the global injectable drug delivery sector<\/strong>. As smart pump capabilities continue to evolve, their usage in perioperative and chronic care settings is accelerating, opening new avenues for product innovation and deployment.<\/p>\n

A notable development is the increasing shift toward ambulatory and homecare settings<\/strong>, where wearable and portable infusion systems are transforming patient management. These solutions enable continuous drug delivery for conditions such as diabetes, cancer, and pain, thereby reducing hospital stays and improving patient convenience. The surge in demand for patient-controlled analgesia (PCA)<\/strong> systems and ambulatory infusion pumps<\/strong> is contributing significantly to market expansion.<\/p>\n

Despite the promising outlook, the market faces challenges. Device recalls and software-related errors have affected user confidence and raised safety concerns. Design flaws such as software bugs, user interface complexities, power failures, and over-infusion events have prompted regulatory scrutiny. The U.S. FDA\u2019s Infusion Pump Improvement Initiative<\/strong>, launched in 2010, aims to address these issues through collaborative device innovation, improved monitoring, and strict compliance standards.<\/p>\n

Nevertheless, manufacturers are responding with continuous R&D efforts and smart feature enhancements. Smart infusion pumps are now being designed with automated drug libraries, real-time alerts, and compliance features to guide clinicians in safe medication administration. These improvements are particularly impactful in managing multi-drug therapies and titrated infusions<\/strong>.<\/p>\n

Regionally, North America dominates the market<\/strong>, with the U.S. accounting for 84.8% of regional sales in 2024<\/strong>. The country\u2019s strong healthcare infrastructure, technological leadership, and regulatory support have fueled widespread adoption of next-generation pumps. Continued investment in patient safety, led by the FDA and leading healthcare providers, will ensure North America remains at the forefront of this market.<\/p>\n

In Europe<\/strong>, Germany holds a significant position, capturing 18.5% of the regional market<\/strong>. The country benefits from its aging population, advanced healthcare system, and commitment to pain management and chronic disease care. Healthcare digitization and increased funding are further boosting demand for smart infusion systems.<\/p>\n

China leads East Asia<\/strong>, holding 54.2% of the market<\/strong> in 2024. Rising cancer prevalence, growing healthcare investment, and a rapidly aging population are key drivers. According to Cancer Communications<\/em>, China recorded over 4.5 million new cancer cases in 2020<\/strong>, with over 3 million deaths<\/strong>, underscoring the urgent need for advanced drug delivery solutions in oncology care.<\/p>\n

From a product standpoint, large volumetric infusion pumps<\/strong> dominate the global market, accounting for 33.3% of total value<\/strong> in 2024. These systems are essential for delivering fluids and medications in precise dosages, especially in critical care settings. They are widely used across hospitals, emergency units, outpatient infusion centers, and long-term care facilities.<\/p>\n

In terms of applications, pain management leads with a 32.6% market share<\/strong>. The growing incidence of chronic pain disorders such as back pain, migraines, and neuropathy\u2014alongside the global burden of diseases\u2014has significantly increased the demand for PCA devices. These systems enable patients to self-administer controlled doses of analgesics, improving satisfaction and reducing workload on clinical staff.<\/p>\n

Among end users, hospitals account for 39.3% of market share<\/strong>, valued at approximately USD 1.1 billion in 2024<\/strong>. This segment is expected to maintain dominance due to the high patient load, increased focus on medication safety, and implementation of cutting-edge infusion systems to reduce hospital stay duration and improve treatment accuracy.<\/p>\n

The competitive landscape is moderately concentrated, with several key players actively investing in product innovation, geographic expansion, and strategic partnerships. Companies such as B. Braun Melsungen AG, Terumo Corporation, Baxter International, Medtronic, Zyno Medical, Fresenius Kabi<\/strong>, and BD (CareFusion)<\/strong> dominate the market.<\/p>\n

Notable industry developments include:<\/p>\n